

# Contents

<b>Introduction</b>	<b>15</b>
<b>History of immune thrombocytopenia (ITP)</b>	<b>18</b>
2.1. Introduction: What is thrombocytopenic bleeding?	18
2.2. History of bleeding	18
2.3. History of the pathogenesis of ITP	20
2.4. History of management of patients with ITP	20
2.5. Actual progress of ITP	22
<b>Basic immunology of immune thrombocytopenia (ITP)</b>	<b>24</b>
3.1. T cell and cytokine abnormalities in ITP	24
3.2. B cell abnormalities	25
3.3. Genetic factors in ITP	25
3.4. Environmental factors in ITP	26
3.5. Alternative modes of B and T cell-mediated thrombocytopenia	26
<b>Megakaryopoiesis in ITP</b>	<b>31</b>
4.1. Overview of normal thrombopoiesis	31
4.2. Thrombopoiesis in ITP: evidence for accelerated platelet destruction	33
4.3. Thrombopoiesis in ITP: evidence for impaired platelet production	33
<b>Platelet function in immune thrombocytopenia</b>	<b>38</b>
5.1. The role of platelet antibodies	38
5.2. Platelet hemostasis	38
5.3. How to assess platelet function in ITP	39
5.4. Estimation of platelet function by flow cytometry	39
5.5. Evaluation of platelet function in patients treated with TPO receptor agonists: experience with eltrombopag	40
<b>Familial Immune Thrombocytopenia (ITP)</b>	<b>43</b>
6.1. Differential diagnostic considerations	43
6.2. Evidence for heredity in ITP	46
<b>Drugs in ITP: mechanisms of action</b>	<b>49</b>
7.1. Steroids	49
7.2. Intravenous immunoglobulin (IVIg)	50
7.3. Anti-D	51
7.4. Rituximab (anti-CD20)	52
7.5. Drugs that stimulate platelet production	53

<b>Standardization of definitions, terminology and outcome criteria: a common language in ITP</b>	<b>58</b>
8.1. Criteria adopted by the IWG to harmonize terminology and definitions in ITP	58
8.2. Primary and secondary ITP and diagnostic platelet count threshold	59
8.3. Definition of the different phases and severity of the disease	60
8.4. Therapeutic goals	61
8.5. Definition of response	61
8.6. Refractory ITP: definition, therapeutic goals and response assessment	63
8.7. Clinical trial-adapted criteria	64
<b>Immune thrombocytopenia in childhood: a problem-oriented review of the management</b>	<b>68</b>
9.1. Clinical presentation and diagnosis	70
9.2. Prevention from and therapy of bleeding	71
9.3. Non-intervention	72
9.4. Intervention	72
9.5. Splenectomy	73
<b>Immune thrombocytopenia in adulthood</b>	<b>76</b>
10.1. Treatment of adult ITP	76
10.1.1. General rules	76
10.1.2. First-line therapy (initial treatment for newly diagnosed patients)	77
10.1.3. Second-line therapy	78
10.1.4. Other second-line therapies	79
10.1.5. New second-line therapies in the management of adults with ITP	80
10.1.6. Patients failing first- and second-line therapies	82
<b>Chronic refractory immune thrombocytopenia</b>	<b>86</b>
11.1. Etiology and risk factors	86
11.1.1. Drug-induced thrombocytopenia	86
11.1.2. Infection-related thrombocytopenia	87
11.2. Therapeutic approach	88
11.2.1. Observation	89
11.2.2. Standard therapy	89
11.2.3. Therapy for refractory disease	89
11.3. Outcomes and sequelae	94
<b>Immune thrombocytopenia in pregnancy</b>	<b>100</b>
12.1. The differential diagnosis of thrombocytopenia during pregnancy	100
12.2. ITP in pregnancy	101
<b>Immune thrombocytopenia – the patients' perspective</b>	<b>106</b>
13.1. Patients "hate steroids"	106
13.2. Rituximab	107
13.3. Patients try to avoid splenectomy	107

13.4.	Patients and Thrombopoietin-Receptor Agonists (TRAs) .....	107
13.5.	Other therapies.....	108
13.6.	The quagmire of modern medicine.....	108
13.7.	What patients really want .....	110
	<b>Decision making in the management of children with ITP</b>	<b>112</b>
14.1.	A preference-sensitive decision .....	112
14.2.	Shared decision making .....	113
	<b>Guidelines for using ITP management guidelines</b>	<b>115</b>
15.1.	Guidelines for management of ITP .....	115
15.2.	Pros and cons of guidelines .....	116
15.3.	Evidence based vs. patient centered management.....	117
	<b>Future considerations of immune thrombocytopenia</b>	<b>119</b>
16.1.	Heterogeneity of ITP .....	119
16.2.	Unknown etiology of ITP .....	120
16.3.	Complex pathogenesis of inflammatory and autoimmune disorders, where ITP is a model	120
16.4.	The question of adequate management of ITP.....	121
	<b>Index</b>	<b>124</b>